DE60122580D1 - 5-4'-2'-(n-methyl-n-(2-pyridyl)amino) ethoxy!benzyl!thiazolidin-2,4-dion mesylatsalz - Google Patents

5-4'-2'-(n-methyl-n-(2-pyridyl)amino) ethoxy!benzyl!thiazolidin-2,4-dion mesylatsalz

Info

Publication number
DE60122580D1
DE60122580D1 DE60122580T DE60122580T DE60122580D1 DE 60122580 D1 DE60122580 D1 DE 60122580D1 DE 60122580 T DE60122580 T DE 60122580T DE 60122580 T DE60122580 T DE 60122580T DE 60122580 D1 DE60122580 D1 DE 60122580D1
Authority
DE
Germany
Prior art keywords
pyridyl
ethoxy
benzyl
amino
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60122580T
Other languages
English (en)
Other versions
DE60122580T2 (de
Inventor
Andrew Simon Craig
Tim Chien Ting Ho
Michael Millan
Deirdre O'keeffe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0031524A external-priority patent/GB0031524D0/en
Priority claimed from GB0031526A external-priority patent/GB0031526D0/en
Priority claimed from GB0031528A external-priority patent/GB0031528D0/en
Priority claimed from GB0031521A external-priority patent/GB0031521D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of DE60122580D1 publication Critical patent/DE60122580D1/de
Application granted granted Critical
Publication of DE60122580T2 publication Critical patent/DE60122580T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60122580T 2000-12-22 2001-12-21 5-4'-2'-(n-methyl-n-(2-pyridyl)amino) ethoxy!benzyl!thiazolidin-2,4-dion mesylatsalz Expired - Fee Related DE60122580T2 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB0031524A GB0031524D0 (en) 2000-12-22 2000-12-22 Novel pharmaceutical
GB0031526A GB0031526D0 (en) 2000-12-22 2000-12-22 Novel pharmaceuticals
GB0031521 2000-12-22
GB0031526 2000-12-22
GB0031528A GB0031528D0 (en) 2000-12-22 2000-12-22 Novel pharmaceutical
GB0031528 2000-12-22
GB0031524 2000-12-22
GB0031521A GB0031521D0 (en) 2000-12-22 2000-12-22 Novel pharmaceutical
PCT/GB2001/005751 WO2002051839A1 (en) 2000-12-22 2001-12-21 5-'4-'2-(n-methyl-n- (2-pyridyl)amino)ethoxy!benzyl!thiazolidine-2, 4-dione mesylate salt

Publications (2)

Publication Number Publication Date
DE60122580D1 true DE60122580D1 (de) 2006-10-05
DE60122580T2 DE60122580T2 (de) 2007-08-30

Family

ID=27447913

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60122580T Expired - Fee Related DE60122580T2 (de) 2000-12-22 2001-12-21 5-4'-2'-(n-methyl-n-(2-pyridyl)amino) ethoxy!benzyl!thiazolidin-2,4-dion mesylatsalz

Country Status (12)

Country Link
US (2) US20040082620A1 (de)
EP (1) EP1349855B1 (de)
JP (1) JP2004520326A (de)
KR (1) KR100840846B1 (de)
CN (1) CN1310912C (de)
AT (1) ATE337313T1 (de)
CY (1) CY1106226T1 (de)
DE (1) DE60122580T2 (de)
DK (1) DK1349855T3 (de)
ES (1) ES2270955T3 (de)
PT (1) PT1349855E (de)
WO (1) WO2002051839A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39384E1 (en) 1993-09-01 2006-11-07 Smithkline Beecham P.L.C. Substituted thiazolidinedione derivatives
DE60217168T2 (de) * 2001-11-21 2007-10-04 Smithkline Beecham Plc, Brentford 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dion-benzolsulfonat; prozess zu seiner herstellung; polymorphe i, ii und iii davon; und seine verwendung als pharmazeutischer wirkstoff
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
PL1694363T3 (pl) * 2003-12-16 2014-07-31 Nektar Therapeutics Monodyspersyjne kompozycje PEGylowanego naloksolu
DE102005034406A1 (de) * 2005-07-22 2007-02-01 Ratiopharm Gmbh Neue Salze von Rosiglitazon
US7435741B2 (en) * 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
EP2062880A1 (de) 2007-11-22 2009-05-27 Bayer Schering Pharma Aktiengesellschaft 5-[(3,3,3-Trifluor-2-hydroxy-1-arylpropyl)amino]-1H-chinolin-2-one, Verfahren zu ihrer Herstellung und ihre Verwendung als entzündungshemmende Wirkstoffe
PL2621496T5 (pl) 2010-09-30 2019-05-31 Astrazeneca Ab Krystaliczny koniugat naloksol-peg

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0842925A1 (de) * 1987-09-04 1998-05-20 Beecham Group Plc Substituierte Thiazolidindionderivate
US5741803A (en) * 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
ATE337313T1 (de) 2006-09-15
CN1491224A (zh) 2004-04-21
KR100840846B1 (ko) 2008-06-23
US7291740B2 (en) 2007-11-06
CN1310912C (zh) 2007-04-18
JP2004520326A (ja) 2004-07-08
DE60122580T2 (de) 2007-08-30
US20060040993A1 (en) 2006-02-23
EP1349855B1 (de) 2006-08-23
PT1349855E (pt) 2006-12-29
KR20030064855A (ko) 2003-08-02
CY1106226T1 (el) 2011-06-08
US20040082620A1 (en) 2004-04-29
ES2270955T3 (es) 2007-04-16
DK1349855T3 (da) 2006-12-27
WO2002051839A1 (en) 2002-07-04
EP1349855A1 (de) 2003-10-08

Similar Documents

Publication Publication Date Title
AP1545A (en) Hydrochloride salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione.
CY1106226T1 (el) Μεσυλικο αλας 5-[4-[2-(ν-μεθυλ-ν-(2-πυριδυλ)αμινο)αιθοξυ]βενζυλ]θειαζολιδινο-2,4-διονης
CY1105354T1 (el) Ένα παραγωγο θειαζολιδινοδιονης και η χρηση του σαν αντι-διαβητικο
RS50136B (sr) Derivati tiazolidindiona i njihova upotreba kao antidijabetika
AP1715A (en) The hydrochloride salt of 5-[ 4 -[2 -(n-methyl-n- (2-pyridyl) amino) ethoxy]benzyl]thiazolidine -2,4-dione
DE60212434D1 (de) Rosiglitazon-edisylate und ihre verwendung als antidiabetika
AP1814A (en) Tartrate salts of thiazolidinedione derivative.
TR200103041T2 (tr) Yeni farmas”tik maddeler.
AP1785A (en) Tartrate salt of thiazolidinedione derivative.
MXPA02012100A (es) Sal de tiazodilindiona para el tratamiento de la diabetes mellitus.
CY1107767T1 (el) Παραγωγο θειαζολιδινοδιονης και χρηση αυτου σαν αντιδιαβητικο
DE60124119D1 (de) Ein thiazolidindionderivat und seine verwendung als antidiabetikum
AP2002002684A0 (en) 5-(4-(2-(n-methyl-n-(2- pyridyl) amino)ethoxy) benzyl) thiazolidine-2, 4-dione hydriodide as pharmaceutical.5-(4-(2-(n-methyl-n-(2- pyridyl) amino)ethoxy) benzyl) thiazolidine-2, 4-dione hydriodide as pharmaceutical.5-(4-(2-(n-methyl-n-(2- pyridyl) amino)ethoxy) benzyl) thiazolidine-2, 4-dione hydriodide as pharmaceutical.5-(4-(2-(n-methyl-n-(2-pyridyl) amino) ethoxy)benzyl) thiazolidine-2,4-dione hydriodide as pharmaceutical
AP2003002737A0 (en) Tartrate salts of thiazolidinedione derivatives
HK1068884A1 (en) 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyleof; and its use as pharmaceutical active ingredie)thiazolidine-2,4-dione benzenesulfonate; process for its preparation; polymorphs i, ii and iii thernt
AP1813A (en) Tartrate salts of thiazolidinedione derivative.
SI1265893T1 (sl) Hidrokloridne soli 5-(4-(2-(n-metil-n-(2-piridil)amino)etoksi)benzil)tiazolidin-2,4-diona
ECSP003434A (es) Nuevos compuestos

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee